News stories about Cronos Group (NASDAQ:CRON) have been trending positive this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cronos Group earned a media sentiment score of 0.28 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.6707242574833 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:

Shares of CRON stock traded up $0.06 during trading hours on Thursday, hitting $7.03. The company’s stock had a trading volume of 40,428 shares, compared to its average volume of 3,516,897. The company has a market capitalization of $1.23 billion and a P/E ratio of 703.00. The company has a debt-to-equity ratio of 0.04, a current ratio of 20.68 and a quick ratio of 15.92. Cronos Group has a 12-month low of $1.00 and a 12-month high of $11.90.

Cronos Group (NASDAQ:CRON) last released its quarterly earnings data on Monday, April 30th. The company reported $0.01 EPS for the quarter. The business had revenue of $1.27 million for the quarter. Cronos Group had a net margin of 35.12% and a return on equity of 2.74%. sell-side analysts forecast that Cronos Group will post -0.01 earnings per share for the current year.

Several research firms have recently commented on CRON. Canaccord Genuity lowered shares of Cronos Group from a “hold” rating to a “sell” rating in a research note on Tuesday, May 1st. GMP Securities upgraded shares of Cronos Group from a “hold” rating to a “buy” rating in a research note on Friday, April 6th. Finally, Beacon Securities reiterated a “buy” rating on shares of Cronos Group in a research note on Friday, May 4th.

About Cronos Group

Cronos Group Inc, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations (?MMPR?). The firm typically invests in companies based in Canada.

Insider Buying and Selling by Quarter for Cronos Group (NASDAQ:CRON)

Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with's FREE daily email newsletter.